Hims & Hers Health (NYSE:HIMS) Price Target Raised to $23.00

Hims & Hers Health (NYSE:HIMS) had its price objective lifted by Bank of America from $20.00 to $23.00 in a research report report published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

HIMS has been the subject of a number of other reports. TD Cowen raised their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Jefferies Financial Group raised their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.07.

Hims & Hers Health Trading Down 1.9 %

HIMS opened at $22.36 on Monday. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $25.74. The firm has a market capitalization of $4.80 billion, a PE ratio of -2,236.00 and a beta of 1.06. The firm’s 50-day moving average price is $16.70 and its 200 day moving average price is $17.50.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s revenue was up 51.8% on a year-over-year basis. During the same period last year, the company posted ($0.03) EPS. As a group, analysts predict that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 835,911 shares of company stock worth $14,640,096 in the last three months. 17.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC raised its position in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares during the period. Victory Capital Management Inc. boosted its holdings in Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Finally, Swiss National Bank increased its holdings in Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after buying an additional 2,000 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.